Supriya Lifescience

Supriya Lifescience ROIC

The Return on Invested Capital (ROIC) of Supriya Lifescience (SUPRIYA.NS) as of Oct 16, 2026 is 17.38 %. In the previous year, Return on Invested Capital (ROIC) was 18.76 % — a change of -7.33% (lower).

ROIC

17.38 %

YoY

-7.33%

Last updated:

Return on Invested Capital (ROIC) of Supriya Lifescience is 2026 17.38 % . Return on Invested Capital (ROIC) of Supriya Lifescience was 2025 18.76 % . It decreases by -7.33% lower compared to the previous year.

The Supriya Lifescience ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2019
21.18 INR
Jan 1, 2020
31.41 INR
Jan 1, 2021
36.23 INR
Jan 1, 2022
23.61 INR
Jan 1, 2023
12.45 INR
Jan 1, 2024
14.51 INR
Jan 1, 2025
18.76 INR
Jan 1, 2026
17.38 INR
The Supriya Lifescience ROIC history
YEARROICYoY
17.38 %-7.33%
18.76 %+29.25%
14.51 %+16.58%
12.45 %-47.27%
23.61 %-34.84%
36.23 %+15.35%
31.41 %+48.31%
21.18 %+348.95%
4.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Supriya Lifescience Stock analysis

What does Supriya Lifescience do? Supriya Lifescience Ltd is a pharmaceutical company based in Mumbai, India, operating within the healthcare sector. The company specializes in the research, development, and manufacturing of active pharmaceutical ingredients (APIs), with a focus on niche therapeutic segments. It employs 392 full-time staff and completed its initial public offering (IPO) on December 28, 2021. The firm's manufacturing facilities are located in Maharashtra, and it exports products to approximately 86 countries. Its product portfolio includes APIs for antihistamines, anesthetics, anti-asthma treatments, and other therapeutic areas such as analgesics and vitamins. Specific products mentioned include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride. The company is engaged in the production of bulk drugs and pharmaceutical chemicals, serving global markets through its export activities. It operates with a focus on niche API products, addressing specific therapeutic needs across multiple categories. The company's website is https://supriyalifescience.com/. Supriya Lifescience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Supriya Lifescience stock

Return on Invested Capital (ROIC) of Supriya Lifescience is 17.38 % in 2026.

Return on Invested Capital (ROIC) of Supriya Lifescience changed from 18.76 % to 17.38 %, representing a -7.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Supriya Lifescience since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Supriya Lifescience with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Supriya Lifescience

All Key Metrics — Supriya Lifescience